2Groszmann R J, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right [ J ]. Hepatology, 2004, 39(2) :280-282.
3de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno 1V consensus workshop on methology of diagnosis and therapy in portal hypertension [ J]. J Hepatol, 2005,43 (1) : 167-176.
4Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis[ J]. J Hepatol, 2014,60(3) :643-653.
5Vlaehogiannakos J, Kougioumtzian A, Triantos C, et ah Clinical trial: The effect of somatostatin vs. octreotide in preventing post- endoscopic increase in hepatic venous pressure gradient in cirrhosis with bleeding varices [ J ]. Aliment Pharmacol Ther, 2007, 26(11-12) : 1479-1487.
6Garcia-Tsao G, Sanyal A J, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in eirrhosis[J]. Hepatology, 2007, 46(3) : 922-938.
7Gareia-Tsao G, Lira JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program [ J ]. Am J Gastroentero1,2009. 104 (7) : 1802-1829.
8Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis [ J]. Hepatology, 2012, 56 (5) : 1883-1992.
9Simonetto DA, Shah VH, Kamath PS. Primary prophylaxis of variceal bleeding [ J ]. Clin Liver Dis, 2014,18 (2) :335-345.
10Vorobioff JD, Groszmann RJ. Prevention of portal hypertension : from variceal development to clinical decompensation [ J ]. Hepatology, 2015, 61 ( 1 ) :375-381.
